Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Impact of Molecular Markers and Cytogenetic Abnormalities on Long-Term Overall Survival and Disease-Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Acute Myeloid Leukemia (AML) patients

Mauricette Michallet, MD, PhD, Mohamad Sobh, PhD, Xavier Thomas, MD, Carole Charlot, Fiorenza Barraco, MD, Giovanna Cannas, MD, Franck E Nicolini, MD, PhD, Emmanuelle Nicolas-virelizier, MD, Claudiu Plesa, MD, Youcef Chelghoum, MD, Jacques Troncy, MD, jean-Pierre Magaud, MD, PhD, Isabelle Tigaud, Sandrine Hayette

Blood (2008) 112 (11): 4476.

https://doi.org/10.1182/blood.V112.11.4476.4476

Published: 2008

Journal Articles

Standard and Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantations (HSCT) from Related and Unrelated Donors for Chronic Lymphocytic Leukemia (CLL). a Long-Term Follow-up (10 years) Study from the EBMT Registry. (CLL Sub-Committee on Behalf of EBMT CLWP)

Mauricette Michallet, MD, PhD, Quoc Hung Le, MD, Peter Dreger, Mohamad Sobh, PhD, Dietger Niederwieser, MD, Vladimir Koza, MD, Tapani Ruutu, Nigel H. Russell, MD, Leo Verdonck, Donald Milligan, MD, MBChB, Nathalie Dhedin, Tomas Kozak, MD, PhD, Marc Boogaerts, MD, PhD, Juergen Finke, Nathalie Tedone, Anja Van Biezen, Ronald Brand, Theo de Witte on behalfhe European Group for Blood Marrow Transplantation

Blood (2008) 112 (11): 566.

https://doi.org/10.1182/blood.V112.11.566.566

Published: 2008

Journal Articles

Impact of Pre-Transplantation, Mobilization and Graft Variables on Transplant Outcome after Autologus Hematopoietic Stem Cell Transplantation in Multiple Myeloma in Patients

Mauricette Michallet, MD, PhD, Quoc Hung Le, MD, Mohamad Sobh, PhD, Nicole Raus, Melissa Clarck, Jean Vial, Gilles Clapisson, Carole Paillet, Franck E Nicolini, MD, PhD, Jacques Troncy, MD, Xavier Thomas, MD, Youcef Chelghoum, MD, Emmanuelle Nicolas-Vierlizier, MD, Giovanna Cannas, MD, Claudiu Plesa, MD, Fiorenza Baracco, MD

Blood (2008) 112 (11): 5137.

https://doi.org/10.1182/blood.V112.11.5137.5137

Published: 2008

Journal Articles

Long-Term Follow-up of Multiple Myeloma Patients Treated by Bortezomib (Velcade ® ): A Study on Efficacy, Tolerance, Survival and Time to Progression

Mauricette Michallet, MD, PhD, Mohamad Sobh, PhD, Quoc Hung Le, MD, Fiorenza Barraco, MD, Charles Dumontet, MD, PhD, Youcef Chelghoum, MD, Emmanuelle Nicolas-Virelizier, MD, Xavier Thomas, MD, Aline Praire, Claudiu Plesa, MD, Giovanna Cannas, MD, Franck Emmanuel Nicolini, MD, PhD, Jacques Troncy, MD

Blood (2008) 112 (11): 5197.

https://doi.org/10.1182/blood.V112.11.5197.5197

Published: 2008

Journal Articles

Double Cord Blood Cell (CBC) Hematopoietic Stem Cell Transplantation after Standard or Reduced Intensity Conditioning: Report of the SFGMTC Registry.

Blood (2008) 112 (11): 1972.

https://doi.org/10.1182/blood.V112.11.1972.1972

Published: 2008

Journal Articles

Updated Analysis of Allogeneic HSCT after RIC for Hematological Malignancies from the Société Française de Greffe de Moelle Osseuse et de Thérapie Cellulaire (SFGM-TC) Registry.

Mauricette Michallet, MD, PhD, Quoc-Hung Le, MD, Mohamad Mohty, MD, PhD, Franck E. Nicolini, MD, PhD, Jean-Michel Boiron, MD, Hélène Espérou, MD, Michel Attal, MD, PhD, Noel Milpied, MD, Bernard Lioure, MD, Pierre Bordigoni, MD, Ibrahim Yackoub-Agha, MD, PhD, Jean-Henri Bourhis, MD, PhD, Bernard Rio, MD, Eric Deconninck, MD, Marc Renaud, MD, Mohamad Sobh, PhD, Nicole Raus, Didier Blaise, MD

Blood (2007) 110 (11): 1085.

https://doi.org/10.1182/blood.V110.11.1085.1085

Published: 2007

Journal Articles

High Response Rate and Improved Graft-Versus-Host Disease (GVHD) Following Bortezomib as Salvage Therapy after Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation (RIC allo-SCT) for Multiple Myeloma (MM).

Jean El-Cheikh, MD, Mauricette Michallet, MD, Arnon Nagler, MD, Hugues de Lavallade, MD, Frank E. Nicolini, MD, Avichai Shimoni, MD, Catherine Faucher, MD, Mohamad Sobh, PhD, Daniela Revesz, MD, Izhar Hardan, MD, Sabine Furst, MD, Didier Blaise, MD, Mohamad Mohty, MD, PhD

Blood (2007) 110 (11): 1080.

https://doi.org/10.1182/blood.V110.11.1080.1080

Published: 2007

NARROW

Impact of Molecular Markers and Cytogenetic Abnormalities on Long-Term Overall Survival and Disease-Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Acute Myeloid Leukemia (AML) patients

Standard and Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantations (HSCT) from Related and Unrelated Donors for Chronic Lymphocytic Leukemia (CLL). a Long-Term Follow-up (10 years) Study from the EBMT Registry. (CLL Sub-Committee on Behalf of EBMT CLWP)

Impact of Pre-Transplantation, Mobilization and Graft Variables on Transplant Outcome after Autologus Hematopoietic Stem Cell Transplantation in Multiple Myeloma in Patients

Long-Term Follow-up of Multiple Myeloma Patients Treated by Bortezomib (Velcade ® ): A Study on Efficacy, Tolerance, Survival and Time to Progression

Double Cord Blood Cell (CBC) Hematopoietic Stem Cell Transplantation after Standard or Reduced Intensity Conditioning: Report of the SFGMTC Registry.

Updated Analysis of Allogeneic HSCT after RIC for Hematological Malignancies from the Société Française de Greffe de Moelle Osseuse et de Thérapie Cellulaire (SFGM-TC) Registry.

High Response Rate and Improved Graft-Versus-Host Disease (GVHD) Following Bortezomib as Salvage Therapy after Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation (RIC allo-SCT) for Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

Impact of Molecular Markers and Cytogenetic Abnormalities on Long-Term Overall Survival and Disease-Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Acute Myeloid Leukemia (AML) patients

Standard and Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantations (HSCT) from Related and Unrelated Donors for Chronic Lymphocytic Leukemia (CLL). a Long-Term Follow-up (10 years) Study from the EBMT Registry. (CLL Sub-Committee on Behalf of EBMT CLWP)

Impact of Pre-Transplantation, Mobilization and Graft Variables on Transplant Outcome after Autologus Hematopoietic Stem Cell Transplantation in Multiple Myeloma in Patients

Long-Term Follow-up of Multiple Myeloma Patients Treated by Bortezomib (Velcade ® ): A Study on Efficacy, Tolerance, Survival and Time to Progression

Double Cord Blood Cell (CBC) Hematopoietic Stem Cell Transplantation after Standard or Reduced Intensity Conditioning: Report of the SFGMTC Registry.

Updated Analysis of Allogeneic HSCT after RIC for Hematological Malignancies from the Société Française de Greffe de Moelle Osseuse et de Thérapie Cellulaire (SFGM-TC) Registry.

High Response Rate and Improved Graft-Versus-Host Disease (GVHD) Following Bortezomib as Salvage Therapy after Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation (RIC allo-SCT) for Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only